Introduction
Dendritic cells (DCs) are the most powerful antigen-presenting cells (APCs) playing a crucial role in the induction and maintenance of primary immune responses. 1 They use toll-like receptors (TLRs) to sense their environment for microbial components, such as lipopolysaccharide (LPS), flagellin, lipopeptides or nucleic acids, and therefore initiate specific signaling pathways that lead to distinct immune responses. 2 Triggering of this conserved TLR signal transduction converges in the activation of the transcription factors nuclear factor (NF)-kB and AP-1, which control the expression of key immunoregulatory genes. 3, 4 At first, binding of ligands to TLRs recruits a central adaptor, MyD88, shared by almost all TLRs, with the exception of TLR3. Hereupon, MyD88 associates with members of the interleukin-1 (IL-1) receptor-associated kinase (IRAK) family. These proteins are phosphorylated and dissociate from MyD88, which results in activation of tumor necrosis factor receptor-associated factors (TRAFs). TRAFs in turn activate transforming growth factor-bactivated protein kinase 1, a member of the mitogen-activated protein kinase kinase kinase (MAP3K) family, which ultimately leads to NF-kB activation. In DCs, NF-kB transcription factors direct the expression of genes important for their development, maturation and antigen-presenting function, such as IL-12, tumor necrosis factor (TNF)-a, major histocompatibility complex II and co-stimulatory molecules.
A second signaling pathway diverges from Tak1, which phosphorylates MAP kinases, such as JNK, p38 and ERK, and finally leads to the activation of AP-1.
Interleukin-10 was described as an immunosuppressive and anti-inflammatory cytokine that plays a major role in T-helper cell regulation by inhibition of Th1 responses. 5 In vitro, IL-10 inhibits the cytokine production and antigen-presenting function of DCs, monocytes and macrophages by inhibition of IL-12 production, the expression of major histocompatibility complex class II, the co-stimulatory molecules CD80, CD86, and the DC marker CD83. Consequently, these cells are impaired in their capacity to induce T-cell responses of primed and naive CD4 þ T cells in allogeneic MLRs and clonal proliferation assays. 6, 7 Furthermore, we have earlier shown that the addition of IL-10 to the cell cultures together with granulocyte macrophage colonystimulating factor (GM-CSF) and IL-4 abolished the differentiation of monocytes to DCs. 8 However, the inhibitory effects of IL-10 on DC function are only observed in immature cells, whereas mature DCs are completely resistant to the effects of this cytokine. 6, 7, [9] [10] [11] [12] In different cell types, such as mouse and human macrophages and T cells, the effects of IL-10 are mediated by the inhibition of the activity of NF-kB. 13 Bhattacharyya et al. 14 showed that this applies also to myeloid DCs, pretreated with IL-10, and that NF-kB inhibition was correlated with suppressed Akt and downstream IkB kinase (IKK) activity.
Interleukin-10 receptor signaling is transmitted through the Jak/ Stat pathway. Earlier it was proposed that Stat3 becomes phosphorylated upon IL-10 binding to the receptor, and then translocates to the nucleus, where it functions as a transcriptional activator. An alternative model suggests that Stat3 would function as an adapter protein binding to the IFN alpha receptor 1, thereby providing a binding site on the receptor for PI3K. 15 PI3K, a molecule integrated in the Jak/Stat signaling pathway, plays a crucial role in a broad range of cellular functions in response to extracellular signals. A key downstream effector of PI3K is the serine-threonine kinase Akt, which in response to PI3K activation, phosphorylates and/or finally regulates the activity of a number of targets such as kinases, transcription factors and other regulatory molecules. These targets also include NF-kB, Raf protein kinase and mammalian target of rapamycin (mTOR), which in turn, mediates cell survival and proliferation. 16, 17 According to these facts, the common target of both signaling cascades, MyD88-dependent TLR signaling and PI3K/Akt pathway, is the NF-kB transcription factor.
In our study, we analyzed the function of human monocytederived APCs generated in vitro from peripheral blood monocyte cells (PBMCs) with IL-4 and GM-CSF in the presence of IL-10 upon activation by TLR ligands (TLR2L, TLR3L, TLR4L, TLR7/8L).
Exposure of APCs to IL-10 resulted in a skewed phenotypic maturation in response to stimuli provided by the TLR ligands, a reduced cytokine production such as IL-12, IL-6 or TNF-a and impaired capacity to stimulate T-cell activation. Furthermore, CCR7 up-regulation in cells exposed to TLR stimulation as well as migration towards CCL19/MIP-3b were strongly reduced. As a suitable mechanism for these effects, IL-10 was found to downregulate MyD88, and to decrease TLR-induced nuclear expression of the NF-kB transcription factor family members c-Rel and Rel-B, as well as interferon regulatory factor (IRF)-3 and IRF-8. This was not due to the inhibition of the MAP kinase pathway as phosphorylation of p38 was not affected but was rather mediated by inhibitory effects on the PI3K pathway.
In summary, our results demonstrate that IL-10 can inhibit TLR-mediated activation of APCs via a MyD88-dependent and -independent pathway.
Materials and methods

Generation of APCs from adherent PBMCs
Antigen-presenting cells were generated from PBMCs as described earlier. 18, 19 In brief, PBMCs were isolated by Ficoll/ Paque (Biochrom, Berlin, Germany) density gradient centrifugation of blood obtained from buffy coats of healthy volunteers from the blood bank of the University of Tü bingen. Cells were seeded (1 Â 10 7 cells per 3 ml per well) into six-well plates (Corning, Cambridge, MA, USA) in serum-free X-VIVO 20 medium (Cambrex Bio Science, Verviers, Belgium). After 2 h of incubation at 37 1C/5% CO 2 , non-adherent cells were removed. GM-CSF (100 ng/ml; Leukine Liquid Sargramostim, Berlex, Richmond, CA, USA) and IL-4 (20 ng/ml; R&D Systems, Wiesbaden, Germany) were added every second day starting at the first day of culture to generate immature DCs. IL-10 (10 ng/ml, R&D Systems) was added from day 0 of the cell culture. Maturation was induced on day 6 by adding one of the following TLR ligands: LPS (TLR4L, 100.0 ng/ml; Sigma-Aldrich, Deisenhofen, Germany), Pam 3 Cys (TLR2L, 5.0 mg/ml; EMC Microcollection, Tü bingen, Germany), Poly I:C (TLR3L, 50.0 mg/ml; Sigma, Deisenhofen, Germany) or R848 (TLR7/8L, 2.0 mg/ml; InvivoGen, San Diego, CA, USA). For generation of monocyte-derived APCs shown in the time course experiments and western blots shown in Figures 7a and b no TLR ligands were added on day 6. Cells were harvested on day 7 for further use.
Immunostaining and FACS analysis
Cells were stained using FITC-or PE-conjugated mouse mAbs against CD1a (Dako Diagnostika, Hamburg, Germany), CD14, CD80, HLA-DR, CD54, (Becton Dickinson, Heidelberg, Germany), CD40, CD86 (PharMingen, Hamburg, Germany), CD83 (Immunotech, Marseille, France), DC-SIGN and CCR7 (R&D Systems), and mouse IgG isotype control (Becton Dickinson). Cells were analyzed on a FACSCalibur cytometer (Becton Dickinson). To calculate the percentage of positive cells, a proportion of 1% false-positive events was accepted in the negative control samples throughout. All FACS analyses were performed at least three times.
MLR assay
After 7 days in culture, as described above, the monocytederived APCs were inactivated by g-radiation at 30 Gy, 100% for 12 min and were seeded into 96-well flat-bottomed micro plates (Greiner Bio-One, Frickenhausen, Germany) at concentrations of 1 Â 
Cytokine determination
Enzyme-linked immunosorbent assay was performed to determine the cytokine concentrations of IL-6, IL-12 and TNF-a (Beckmann Coulter, Hamburg, Germany) following the manufacturer's instructions, and experiments were repeated multiple times.
Migration assay
At day 7 of the culture, cells were seeded into 8 mm transwell chambers (BD Falcon, Heidelberg, Germany) at a density of 2 Â 10 5 per well. Macrophage inflammatory protein-3b (Mip-3b) was used as chemotaxis stimulus at a concentration of 100 ng/ ml, diluted in RPMI-medium (GIBCO, Invitrogen, Karlsruhe, Germany). After incubation for 3 h at 37 1C/5% CO 2 , the number of migrated APCs was counted using a FACSCalibur cytometer (Becton Dickinson).
Experiments were repeated for three times.
Analysis of phagocytic capacity
For the analysis of phagocytic activity, 2 Â 10 5 monocytederived APCs were cultured with GM-CSF and IL-4 and treated with IL-10 and/or the TLR-2 ligand Pam3Cys for 48 h. Cells were then incubated with FITC-dextran (40 000 molecular weight, Molecular Probes-Invitrogen) for 1 h at 37 1C. As a control, 2 Â 10 5 cells were precooled to 4 1C before the incubation with dextran at 4 1C for 1 h. The cells were washed four times and immediately analyzed on a FACSCalibur cytometer.
Polyacrylamide gel electrophoresis and western blotting
Nuclear extracts were prepared from monocyte-derived APCs at the following points of time: 24, 48, 72 h and 7 day as described previously. 20 For the preparation of whole-cell lysates, cells were lysed in a buffer containing 1.0% Igepal, 0.5% sodium deoxycholate, 0.1% SDS, 2.0 mM EDTA, 1.0 mM phenylmethylsulfonyl fluoride and 2.0 mg/ml aprotinin, as well as protease inhibitors at the same points of time.
Protein concentrations were determined using a BCA assay (Pierce, Perbio Science, Bonn, Germany). For the detection of nuclear localized transcription factors, approximately 20.0 mg nuclear extracts were separated on a 10% SDS-polyacrylamide gel and transferred onto nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany). Ponceau S staining of the membranes was performed to confirm that equal amounts of protein were present in every lane. The blot was probed with antibodies for Rel-B (C-19, rabbit polyclonal), c-Rel (B-6, mouse monoclonal), IRF-3 (C-20, goat polyclonal) or IRF-8 (goat polyclonal) all from Santa Cruz Biotechnology (Santa Cruz, CA, USA). ESE 3a antibody (5.A5, rat monoclonal) was kindly provided by A Tugores.
The activation state of the MAP kinases p38 and ERK, as well as MyD88, IRAK1, TRAF6, PU-1, Stat3, Osteoactivin, TLR2, TLR3 and mTor levels, were determined by separating 20.0-40.0 mg whole-cell lysates on a 10 or 6% SDS-polyacrylamide gel and subsequent transfer to nitrocellulose membranes. These were probed with antibodies specific for Erk1 (C-16, rabbit polyclonal), MyD88 (N-19, goat polyclonal), IRAK1 (F-4, mouse monoclonal), TRAF6 (D-10, mouse monoclonal), TLR3 (M-300, rabbit polyclonal) and TLR4 (H-80, rabbit polyclonal) all purchased from Santa Cruz Biotechnology. Phospo-p38 (Thr180/Tyr182, rabbit polyclonal), p38 (rabbit polyclonal), Phospho-Erk1 (Thr202/Tyr204, rabbit polyclonal), mTor (7C10, rabbit monoclonal), Phospho-mTor (Ser2448, rabbit polyclonal) were purchased from Cell Signaling Technology, New England Biolabs, Frankfurt, Germany. Antibody specific for hOsteoactivin (AF2550, goat polyclonal) was purchased from R&D Systems, Minneapolis, USA and TLR2 (24-9028, rabbit polyclonal) antibody was purchased from eBioscience Inc., San Diego, CA, USA. Western blots were performed 3-10 times.
Reverse transcription-PCR
Total RNA was isolated from cell lysates of (1 Â 10 6 cells) APCs using QIAGEN RNeasy Mini anion-exchange spin columns (QIAGEN, Hilden, Germany), according to the instructions of the manufacturer. A quantity of 0.5 mg of total RNA was subjected to a 20.0 ml cDNA synthesis reaction using the Transcriptor First-Strand cDNA Synthesis Kit (Roche, Mannheim, Germany) and random primers. A volume of 1.0 ml of cDNA was subjected to PCR (32 cycles) as described earlier. 21, 22 The integrity of the RNA and the efficiency of the cDNA synthesis were checked by amplifying the b2-microglobulin gene with an intron-spanning primer pair. Primer sequences were deduced from published cDNA sequences: ERK2 5 0 -ccacc catatctggagcagt-3 0 and 5 0 -cagtcctctgagcccttgtc-3 0 , IRAK1 5 0 -gacc ctgtctctgccaaaaa-3 0 and 5 0 -caggctggagtgcagtcata-3 0 and MyD88 5 0 -gcacatgggcacatacagac-3 0 and 5 0 -gacatggttaggctccctca-3 0 . Remaining sequences were published elsewhere. 21, 22 The semiquantitative estimation of target gene expression was carried out by normalization of the density volumes of ethidium bromidestained PCR products to the corresponding b2-microglobulin-PCR products (target gene-PCR product [S {pixel, gray values}]/ b2-microglobulin [S {pixel, gray values}]) using a CCD camera and gel analysis system (BioDocAnalyze video, Whatman Biometra, Gö ttingen, Germany). 23 Values were expressed as percentage of the 24 h value with IL-4 and GM-CSF (100%).
Results
IL-10 prevents APC maturation in response to TLR stimuli
Several recent reports showed that IL-10 inhibits IL-12 production, the expression of major histocompatibility complex class II, the co-stimulatory molecules, the DC marker CD83 and abolishes the differentiation of monocytes to DCs. [6] [7] [8] We generated APCs in vitro from PBMCs incubated with IL-10 from the initiation of the 7-day culture (day 0) together with GM-CSF and IL-4. These cells were additionally stimulated with various TLR ligands on day 6, such as LPS (TLR4L), Poly I:C (TLR3L), Pam 3 Cys (TLR2L) or R848 (TLR7/8L).
In accordance with our earlier study, 8 we found that these APCs remained CD14 positive and expressed low levels of CD1a, CD83, CD80 and CD86. Notably, DC-SIGN, a C-type lectin that recognizes a wide variety of pathogens, such as viruses, bacteria, yeast and parasites through the binding of mannose or Lewis-x carbohydrate structures, was upregulated in IL-10-treated APCs (Figure 1a) . This was not due to in vitro effects, as we found similar reduction of surface markers in myeloid DC sorted by MACS-technology from PBMCs of healthy donors (data not shown). In line with the phenotype, IL-10 reduced the capacity of the TLR-activated APCs to stimulate proliferation of T cells in MLRs (Figure 1b) . These effects were reproducibly observed with all used TLR ligands. Representative results for the TLR2 ligand (Pam 3 Cys) are presented in Figure 1 .
IL-10 blunts APC cytokine secretion
In the next set of experiments, we examined whether IL-10 affects the capacity of APCs to produce proinflammatory/ immunostimulatory cytokines, such as IL-12, TNF-a and IL-6, which enhance the response of naive T cells. As shown in Table 1 , the stimulation of monocyte-derived APCs generated in vitro with IL-4 and GM-CSF in the presence of IL-10 with all TLR ligands used, produced significantly lesser amounts of the respective cytokines as compared to the APCs generated in the absence of IL-10.
These results suggested that besides the reduced expression of co-stimulatory molecules, inhibition of key cytokines contributed to the impaired capacity to stimulate T-cell activation.
IL-10 impairs migratory capacity and phagocytosis of monocyte-derived APCs
Upon activation, DCs upregulate the CCR7 receptor and acquire the capacity to migrate in response to CCL19/MIP-3b. This effect is believed to be crucial in vivo to ensure that DCs reach the afferent lymphoid tissues. 24 To analyze this important functional feature of DCs, we performed migration assays using a transwell system in which MIP-3b was utilized as chemotactic stimulus.
These experiments revealed that APCs generated in the presence of IL-10 and stimulated with various TLR ligands, lack the capacity to migrate towards CCL19 (Figure 2a ). In line with these findings, CCR7 expression on APCs generated in the presence of IL-10 and thereafter stimulated with various TLR ligands was reduced as compared to the cells activated in the absence of IL-10. Representative results for TLR3 ligand are presented in Figure 2b .
These findings show that IL-10 abolished the migratory capacity of monocyte-derived APCs, presumably by downregulation of CCR7 cell-surface expression.
We sought to determine the phagocytic capacity of IL-10-treated monocyte-derived APCs. To test this, monocytederived APCs were cultured with GM-CSF and IL-4 and treated with IL-10 and/or the TLR-2 ligand Pam3Cys for 48 h.
For evaluation of phagocytosis, APCs were incubated with FITC-dextran at 37 1C (shaded histograms) and 4 1C (open histograms) and analyzed on a FACSCalibur. We found an increase of FITC-dextran uptake in IL-10-treated DCs indicating IL-10 inhibits TLR-mediated activation of APCs A Knödler et al the previously described differentiation to macrophages (Figure 2c ). 9 Effects of IL-10 on DC intracellular signaling cascades
In the next series of experiments, we sought to analyze signaling pathways involved in the IL-10-mediated effects on TLR ligand stimulation of APCs.
Recently, it has become clear that ligand binding to TLRs induces a large number of genes through activation of NF-kB, MAP kinases and IRFs. 2 Upon ligand binding to TLR2 and TLR4, intracellular signaling is initially transmitted by cytosolic TIR domain-dependent interactions with downstream adaptor protein MyD88. 25 However, MyD88-independent signaling was shown for TLR3 and TLR4.
In our first experiments, we examined MyD88 protein levels by western blotting in APCs generated in vitro with IL-4 and GM-CSF in the presence of IL-10 and subsequent stimulation with various TLR ligands. As shown in Figure 3 , stimulation of IL-10-treated cells with TLR ligands resulted in strongly reduced cytoplasmatic MyD88 protein levels.
In a next step of the signaling cascade, in response to stimuli, the association of TLRs and MyD88 recruits members of the IRAK family. IRAK4 and IRAK1 are sequentially phosphorylated and dissociated from MyD88, which results in the activation of TRAF6, which in turn activates AP-1 and/or NF-kB by phosphorylation of IkBs.
In line with MyD88, no IRAK1 or TRAF6 protein expression was detected when IL-10 was added to the cell cultures, regardless of the TLR ligand utilized (Figure 3 ). These experiments consistently showed that IL-10 blocked the TLR signaling pathways through MyD88, IRAK1 and TRAF6.
In our next set of experiments, we examined the protein expression of p38 as well as its phosphorylated form (pp38) by western blotting. As shown in Figure 3 , we observed no significant differences between the protein levels of this key regulatory protein p38 in APCs generated in vitro with IL-4 and GM-CSF in the presence or absence of IL-10 and stimulated with various TLR ligands, neither for the unphosphorylated nor for the phosphorylated variant. The same findings were obtained for ERK (data not shown). These results showed that the effects of 
IL-10 inhibits TLR-mediated activation of APCs
A Knödler et al IL-10 on TLR stimulation of APCs were not due to the inhibition of the MAP kinase pathway. Members of the transcription factor family NF-kB proteins in mammals play an important role in regulating inflammatory and immune responses. 26, 27 Rel-B is associated with the development and antigen presentation of myeloid DCs. 26, 28 c-Rel was shown to play an essential role in LPS-and CD40L-induced expression of IL-12 and regulates survival of mature DCs. 27 As shown in Figure 4 , IL-10 led to a substantial decrease of nuclear Rel-B protein as compared to the samples stimulated with various TLR ligands in the absence of IL-10. In accordance with these results, no c-Rel protein was detected upon IL-10 treatment in APC nuclear extracts (Figure 4) .
The transcription factor IRF-3 is activated when cells are exposed to LPS, poly I:C or virus infection, and mainly control type I IFN. Upon TLR stimulation, this protein becomes phosphorylated by IKKs, TANK-binding kinase (TBK) 1 and IKKi, translocating into the nucleus to regulate target gene expression. 29, 30 IRF-8 is implicated in TLR9-mediated responses. 31 In APCs treated with IL-10 and subsequently 
A Knödler et al stimulated with various TLR ligands, no IRF-3 or IRF-8 protein was detected in western blots, indicating that the respective TLR signaling pathways were inhibited by this cytokine (Figure 4) . We earlier showed that ESE-3, a member of the Ets transcription factor family, is differentially expressed in human DCs and might be involved in their development. 32 Functionally, this protein has been shown to be a transcriptional repressor of several genes positively regulated by MAP kinase signaling. 33 As ascertained by western blotting, ESE-3 protein was completely eliminated in nuclear extracts obtained from APCs stimulated with various TLR ligands and incubated with IL-10 ( Figure 4) .
As reported recently, inhibition of NF-kB activation by IL-10 is, in part, the consequence of targeting the PI3K pathway. 14 A key downstream effector of PI3K is the serine-threonine kinase Akt, which in response to PI3K activation, phosphorylates and regulates the activity of a number of targets including mTOR.
We investigated the possibility that the PI3K/Akt pathway was involved in the effects observed in APCs treated as above, by monitoring mTOR protein levels. In the samples activated with TLR ligands and treated with IL-10, significantly lesser amounts of mTOR protein were detected by western blot analysis, as compared to the samples without IL-10. This was true for both, the unphosphorylated and the phosphorylated variant of mTOR ( Figure 5 ).
These findings indicated that IL-10 inhibited PI3K signaling pathway in monocyte-derived APCs stimulated with various TLR ligands.
To analyze the kinetics of protein expression in IL-10-treated and untreated monocyte-derived APCs, we prepared whole-cell lysates as well as nuclear extracts at different time points of culture. Western blotting of protein lysates and nuclear extracts of time points 24, 48 and 72 h showed a pronounced downregulation of molecules involved in TLR-mediated signal transduction upon IL-10 treatment, partly already after 48 h. Downregulation of mediators in IL-10-treated APCs could be shown for TLR2, TLR3, TLR4, IRAKI, Stat3, TRAF6, PU-1 and MyD88 (Figure 7a ). We observed a similar modus of downregulation for the transcription factors IRF-3, RelB, IRF-8 and cRel (Figure 7b) .
Interestingly, Osteoactivin, a transmembrane glycoprotein expressed in osteoblasts, DCs and tumor cells, was upregulated under treatment of IL-10 in monocyte-derived APCs (Figure 7a ). Osteoactivin (DC-HIL) impairs APC function, which might be one explanation for the observed IL-10 effect. 12, 34 To further analyze the underlying gene-expression regulatory mechanisms of our previous findings, we performed a semiquantitative reverse transcription-PCR (RT-PCR) analysis to detect mRNA expression of MyD88, IRAK1, TRAF6 and mTOR in APCs generated as above.
In APCs activated with various TLR ligands, the mRNA transcription of all above genes analyzed was not significantly affected by IL-10 ( Figure 6 and not shown).
In summary, our study shows that IL-10 can inhibit TLRmediated activation of APCs through a MyD88-dependent and -independent pathway and that this inhibition is not mediated by transcriptional regulation of the identified genes, involved in various signaling cascades. 
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Discussion
Dendritic cells are the most powerful APCs playing a crucial role in the induction and maintenance of primary immune responses. In vitro, DCs can be generated from CD34 þ progenitor cells cultured with different cytokine combinations or differentiated from CD14 þ PBMCs by adding GM-CSF and IL-4. [35] [36] [37] The design of these protocols made it possible to develop DC-based vaccination studies for the treatment of infectious and malignant diseases.
The TLRs, so called pattern recognition receptors, are part of the innate immune system. They specifically recognize pathogen-associated molecular patterns, such as LPS and viral nucleic acids, and also mediate the uptake of pathogens by phagocytic cells. 38 The TLRs trigger intracellular signaling pathways that result in the induction of host genes, which code for inflammatory cytokines, type I IFN and chemokines. In DCs, TLR-signaling induces 'maturation' by the upregulation of co-stimulatory and human leukocyte antigens molecules. This process is essential for the induction of pathogen-specific immune responses, thus linking innate and adaptive immunity. 39 The conserved signaling pathways used by these receptors, activate inflammatory cytokines such as TNFa, IL-6, IL-1b and IL-12. 40 Inflammatory stimuli provided by TLR2 and TLR4 activate MyD88-dependent signaling pathways that merge in the transcription factors NF-kB and AP-1. Moreover, MyD88-independent pathways activating the IRF-3 transcription factor were described for TLR3 and TLR4. Alternative signal transduction uses a specific combination of adapter molecules to initiate immune responses. TLR3 and TLR4 induce IFN-b through a Trif/TBK1/IKKi/IRF-3-mediated pathway, while TLR7/8 and TLR9 induce type I IFN by DCs through MyD88/IRAK1/IRF-7 signaling. 2 Interluekin-10 is recognized as a key cytokine released by T cells with regulatory activities. Its physiological function is to limit the magnitude of an immune response or to prevent unwanted immune responses. It was initially characterized in the mouse as cytokine synthesis inhibitory factor 41 from con A-stimulated Th2 cells that inhibited the production of cytokines, such as IL-2, TNF-a, IFN-g and GM-CSF by Th1, but not Th2 cells, in response to antigens presented by APCs. The inhibitory effect of IL-10 was only observed when macrophages, but not B cells, Langerhans cells or splenic DCs were used as accessory cells. 42 Other studies showed that the pretreatment of immature DCs with this cytokine effectively suppresses IL-12 and TNF-a secretion after stimulation with LPS or anti-CD40 antibody, as well as the capacity to stimulate CD8 þ T cells. [6] [7] [8] 10, 14, [43] [44] [45] [46] Furthermore, IL-10 regulates the maturation and function of DCs by downregulating the expression of co-stimulatory molecules, including CD80, CD86 and major histocompatibility complex class II. 47, 48 Various signaling pathways involved in the IL-10-mediated effects have been elucidated: IL-10 suppresses TNF-gene expression in LPS-stimulated human macrophages through transcriptional and post-transcriptional events independently of NF-kB, 49 and inhibits LPS-induced activation of macrophages by eliciting expression of suppressor of cytokine signaling 3. 50 We and others have shown that IL-10 prevents nuclear translocation and DNA binding of RelB in human APC precursors or immature DCs. 8, 46 Furthermore, IL-10 effectively regulates the APC function of DCs through suppression of IKK activity and subsequent NF-kB activation. Recently, it has been ascertained that inhibition of NF-kB activation is in part the consequence of IL-10 targeting the PI3K pathway. 14 Little is known about the influence of IL-10 on DCs stimulated with various TLR ligands, how the effects are mediated and how the IL-10 and TLR signaling pathways interact with each other.
In our study, we therefore analyzed the combined influence of various TLR stimuli such as LPS (TLR4L), Pam 3 Cys (TLR2L), Poly I:C (TLR3L) and R848 (TLR7/8L) and IL-10 on the generation and function of DCs in vitro. In line with earlier results, we showed that IL-10 prevents the differentiation of monocyte-dervived APCs when IL-10, GM-CSF and IL-4 are added to the medium on the first day of the culture initiation.
In subsequent experiments, we found that IL-10 inhibited the effects of all TLR-stimuli used, resulting in an inhibition of APC activation. An interesting finding was that DC-SIGN was upregulated upon TLR-stimulation in the presence of IL-10.
Geijtenbeek et al. 51 have showned that the binding of the mannose-capped cell-wall component of mycobacteria tuberculosis (lipoarabinomannan, ManLAM) to DC-SIGN induced the production of the anti-inflammatory cytokine IL-10 by LPSactivated DCs. The authors stated that the inhibition of DC maturation and the induction of IL-10 might contribute to the virulence of mycobacteria. With respect to these data, our findings would suggest a positive feedback-loop in TLRstimulated monocyte-derived APCs, by which IL-10 upregulates DC-SIGN and with it enhances stimulation of this molecule by pathogens and induction of IL-10 ( Figure 1 ).
In our next experiments, we showed that the IL-10-treated APCs are significantly less potent in stimulating allogeneic lymphocyte proliferation that is most likely due to the downregulation of the co-stimulatory molecules (Figures 1 and 2 ) and significantly reduced amounts of the secreted proinflammatory and immunostimulatory cytokines IL-6, IL-12 and TNF-a (Table 1) .
Another important functional ability of DCs is to migrate towards CCL19/MIP-3b. CCR7 was described initially as a potent leukocyte chemotactic receptor that was later shown to be responsible for directing the migration of DCs to the lymph nodes where these cells play an important role in the initiation of the immune response in vivo. CCR7 has two ligands CCL19 and CCL21 that are highly expressed by stromal cells in the T-cell-rich lymph node areas. In addition, CCL19 is expressed by mature DCs and is presented on the luminal side of HEV cells. 24 Maturation takes place concomitantly with the migration of the DCs from their niches in the peripheral tissues to the lymph nodes, where they arrive through the lymphatics.
In our study, we found that the almost complete loss of the ability of APCs to migrate towards CCL19 correlated with downregulation of the CCR7 receptor in APCs treated with IL-10, suggesting an underlying causality.
We next analyzed possible signaling pathways, involved in the effects of IL-10, by systematic investigation of TLR-mediated signaling cascades, as well as pathways that were described to be involved in IL-10 signal transduction.
In western blot analysis, we found that protein levels of major components involved in TLR signaling, such as MyD88, IRAK1, TRAF6 and the transcription factors c-Rel and RelB, were decreased upon IL-10 treatment. This was also true for the pathway utilizing the IRF-transcription factors, as IRF-3 and IRF-8 protein levels were dramatically decreased in IL-10-treated cells.
Earlier studies that have analyzed the effects of IL-10 upon the NF-kB signaling pathway consigned a rather inconsistent scenario. They comprised regulation of transcription, 13 prevention of the degradation of IkBa and thereby the translocation of NF-kB to the nucleus and its activation of cytokine production, blocking the activity of the IKK molecule, thereby preventing the IL-10 inhibits TLR-mediated activation of APCs A Knödler et al degradation of IkB, 52, 53 reduction of IkBa degradation and inhibition of serine phosphorylation of p65 14 or inhibition of the recruitment of RNA polymerase II to the promoter. 54 Recently, it was reported that IL-10 mediates its effects through the Jak/Stat pathway. The central protein kinases of this pathway are PI3K and Akt, which downstream target mTOR. Another target of Akt is the IKK, which phoshorylates IkBs, thereby releasing NFkB transcription factors. Thus, Akt links the Jak/Stat pathway and TLR signaling through IKKs. An involvement of the PI3K pathway was confirmed by showing significantly reduced mTOR levels in APCs treated with IL-10 ( Figure 5) .
We observed that IL-10 treatment resulted in decreased levels of protein expression upstream of IKKs, such as MyD88, IRAK and TRAF6. Decrement was made obvious in time course experiments beginning after 48 h of culture with IL-10 ( Figure 7) .
To further analyze the underlying regulatory mechanism(s), we additionally performed semiquantitative RT-PCR assays for the genes identified to be involved in the IL-10-mediated effects. In contrast to real time quantitative RT-PCR, this technique only allows an estimation of the level of gene expression. However, as shown in Figure 6 , the standard deviations of triplicate experiments were rather low, indicating reliable data. Owing to the complete inhibition of protein expression on day 7, one would easily detect any transcriptional regulation by semiquantitative RT-PCR. Summarized, these analyses revealed no transcriptional regulation of MyD88, IRAK1, TRAF6 and mTOR. This suggests post-transcriptional regulation of protein levels. Remarkably, various proteins along the entire TLR signaling cascade were affected, suggesting an associated post-transcriptional regulation of a mechanistically linked group of proteins. Application of proteasomal inhibitors bortezomib and lacatcystin and autophagy inhibitor LY-294.002 showed no influence on diminishing protein levels of mentioned mediators, indicating that degradation is not solely due to proteasomal acitivity or autophagy.
In conclusion, our study showed that IL-10 massively interfered with TLR-mediated activation of APCs by inhibition of MyD88-dependent and -independent pathway and this inhibition was not regulated on the transcription level.
These results show novel mechanisms involved in inhibitory effects of IL-10 on multiple functions of human DCs, the most potent APCs. IL-10 is secreted by neoplastic cells derived from a wide range of malignancies. Elevated serum levels of IL-10 can be detected in cancer patients that correlate with the tumor burden, a poor prognosis and treatment outcome and result in a profound immunosuppression. Furthermore, recently it was shown that regulatory T cells that can de found with increased frequencies in tumor and leukemic patients can produce IL-10 and suppress the function of APCs and antigen-specific immune T lymphocytes. Our results provide new insights in the action of IL-10 and might be of relevance for the design and development of immunotherapeutic approaches by targeting IL-10 in cancer patients. 
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